GILEAD SCIENCES, INC. Derivative Asset Fair Value After Offset And Deduction Subject To Master Netting Arrangement
GILEAD SCIENCES, INC. (GILD) had Derivative Asset Fair Value After Offset And Deduction Subject To Master Netting Arrangement of $65.00 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Offsetting › Offsetting Derivative Assets › Derivative Asset, Subject to Master Netting Arrangement, after Offset and Deduction
us-gaap:DerivativeAssetFairValueAfterOffsetAndDeductionSubjectToMasterNettingArrangement · last filed 2026-08-06
- 2026-06-30: Derivative Asset Fair Value After Offset And Deduction Subject To Master Netting Arrangement $65.00M.
- 2026-03-31: Derivative Asset Fair Value After Offset And Deduction Subject To Master Netting Arrangement $49.00M.
- 2025-12-31: Derivative Asset Fair Value After Offset And Deduction Subject To Master Netting Arrangement $16.00M.
- 2025-09-30: Derivative Asset Fair Value After Offset And Deduction Subject To Master Netting Arrangement $2.00M.
| Period end | Derivative Asset Fair Value After Offset And Deduction Subject To Master Netting Arrangement |
|---|---|
| 2026-06-30 | $65.00M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $49.00M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $16.00M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $2.00M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-07 |
| 2024-12-31 | $125.00M 10-K · filed 2026-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |